• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

Sage Therapeutics - Articles and news items

SAGE achieves 77% response rate in Phase 1/2 clinical trial of SAGE-547 in super-refractory status epilepticus

Industry news / 15 May 2015 / Victoria White

SAGE-547 demonstrated robust activity, with a 77% response rate in patients with SRSE, in a successfully completed Phase 1/2 clinical trial…

 

Webinar: Understanding ISO Standards: ISO 14644-2:2015 Cleanroom MonitoringWATCH NOW
+ +